Trial Outcomes & Findings for Sickle Cell Disease (SCD) Bone Pain Study (NCT NCT05283148)

NCT ID: NCT05283148

Last Updated: 2025-08-24

Results Overview

Areal bone mineral density of the lumbar spine measured by dual-energy X-ray absorptiometry (DXA) scan and reported in grams per square centimeter.

Recruitment status

ACTIVE_NOT_RECRUITING

Study phase

NA

Target enrollment

53 participants

Primary outcome timeframe

Baseline

Results posted on

2025-08-24

Participant Flow

One hundred and twenty-eight unique adults (age 18 years and older) with SCD of any genotype seen in the Adult Sickle Cell clinic at UCD's Comprehensive Cancer Center between 2022-2023 were eligible to participate in the SCD Bone Pain study.

From this convenience sample of 128 SCD adults, 72 were approached to participate in the study, and 53 participants eventually enrolled in the SCD Bone Pain study

Participant milestones

Participant milestones
Measure
SCD Bone Pain Study Cohort
The SCD Bone Pain study was a single-arm, prospective, observational cohort study of 53 adults with sickle cell disease (SCD) undergoing research DXA scans to assess bone mineral density, thoracolumbar morphometry for vertebral fracture analyses, and ASC-Me pain impact assessment. Definitions: Dual-energy X-ray absorptiometry (DXA) scan: Used to measure bone mineral density at the lumbar spine, total hip, forearm, and whole body Vertebral fracture analysis (VFA): Obtained from thoracolumbar morphometry in DXA scanner, then grade presence and severity of vertebral compression fractures using spinal deformity index Adult Sickle Cell Quality of Life Measurement System (ASCQ-Me) pain impact questionnaire: Calculate patient-reported total pain scores to determine the pain phenotype of each study participant
Overall Study
STARTED
53
Overall Study
COMPLETED
53
Overall Study
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Sickle Cell Disease (SCD) Bone Pain Study

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
SCD Bone Pain Study Cohort
n=53 Participants
Prospective cohort of 53 adults with sickle cell disease (SCD) to assess the following: 1. Bone mineral density (BMD) at the lumbar spine, left total hip, left forearm, and whole body, using a dual-energy X-ray absorptiometry (DXA) scan 2. Spinal deformity index (measure of presence and severity of vertebral fractures) using thoracolumbar morphometry obtained from the DXA scanner 3. Patient-reported pain impact score obtained from the Adult Sickle Cell Quality of Life Measurement System (ASCQ-Me) Pain impact questionnaire
Age, Continuous
36 Years
n=99 Participants
Sex: Female, Male
Female
34 Participants
n=99 Participants
Sex: Female, Male
Male
19 Participants
n=99 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
2 Participants
n=99 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
51 Participants
n=99 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=99 Participants
Race (NIH/OMB)
Asian
0 Participants
n=99 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=99 Participants
Race (NIH/OMB)
Black or African American
50 Participants
n=99 Participants
Race (NIH/OMB)
White
1 Participants
n=99 Participants
Race (NIH/OMB)
More than one race
2 Participants
n=99 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
Region of Enrollment
United States
53 Participants
n=99 Participants
Height
172 cm
n=99 Participants
Body mass index (BMI)
24.6 kg/m2
n=99 Participants
Sickle cell disease (SCD) genotype
Hb SS
30 Participants
n=99 Participants
Sickle cell disease (SCD) genotype
Hb SC
15 Participants
n=99 Participants
Sickle cell disease (SCD) genotype
Hb SB0
5 Participants
n=99 Participants
Sickle cell disease (SCD) genotype
Hb SB+
2 Participants
n=99 Participants
Sickle cell disease (SCD) genotype
Hb SD
1 Participants
n=99 Participants
Osteonecrosis
Yes
22 Participants
n=99 Participants
Osteonecrosis
No
31 Participants
n=99 Participants

PRIMARY outcome

Timeframe: Baseline

Areal bone mineral density of the lumbar spine measured by dual-energy X-ray absorptiometry (DXA) scan and reported in grams per square centimeter.

Outcome measures

Outcome measures
Measure
Group A
n=34 Participants
Female participants
Group B
n=19 Participants
Male Participants
Lumbar Spine Bone Mineral Density
0.97 g/cm2
Interval 0.62 to 1.31
1.0 g/cm2
Interval 0.72 to 1.67

PRIMARY outcome

Timeframe: Baseline

Number of standard deviations between measured lumbar spine bone mineral density (g/cm2) for each participant and mean lumbar spine bone mineral density (g/cm2) of the reference population. A Z-score of 0 represents the mean of the reference population. A negative Z-score means the measured bone mineral density values are lower (worse) the reference mean, while positive Z-scores mean they are above/higher. Bone mineral density Z-scores ≤ -2 indicates low bone density.

Outcome measures

Outcome measures
Measure
Group A
n=34 Participants
Female participants
Group B
n=19 Participants
Male Participants
Lumbar Spine Bone Mineral Density-Z-scores
-1.35 Z-score
Interval -4.4 to 1.6
-1.60 Z-score
Interval -4.3 to 4.3

PRIMARY outcome

Timeframe: Baseline

Areal bone mineral density of the total hip measured by dual-energy X-ray absorptiometry (DXA) scan and reported in grams per square centimeter.

Outcome measures

Outcome measures
Measure
Group A
n=34 Participants
Female participants
Group B
n=19 Participants
Male Participants
Total Hip Bone Mineral Density (BMD)
0.90 g/cm2
Interval 0.66 to 1.34
1.03 g/cm2
Interval 0.67 to 1.76

PRIMARY outcome

Timeframe: At enrollment

Number of standard deviations between measured total hip bone mineral density (g/cm2) for each participant and mean total hip bone mineral density (g/cm2) of the reference population. A Z-score of 0 represents the mean of the reference population. A negative Z-score means the measured bone mineral density values are lower (worse) the reference mean, while positive Z-scores mean they are above/higher. Bone mineral density Z-scores ≤ -2 indicates low bone density.

Outcome measures

Outcome measures
Measure
Group A
n=34 Participants
Female participants
Group B
n=19 Participants
Male Participants
Total Hip Bone Mineral Density-Z-scores
-0.75 Z-score
Interval -2.3 to 2.0
-0.5 Z-score
Interval -2.7 to 3.5

PRIMARY outcome

Timeframe: Baseline

Areal bone mineral density of the femoral neck measured by dual-energy X-ray absorptiometry (DXA) scan and reported in grams per square centimeter.

Outcome measures

Outcome measures
Measure
Group A
n=34 Participants
Female participants
Group B
n=19 Participants
Male Participants
Femoral Neck Bone Mineral Density (BMD)
0.77 g/cm2
Interval 0.53 to 1.3
0.94 g/cm2
Interval 0.63 to 1.68

PRIMARY outcome

Timeframe: Baseline

Number of standard deviations between measured lumbar spine bone mineral density (g/cm2) for each participant and mean lumbar spine bone mineral density (g/cm2) of the reference population. A Z-score of 0 represents the mean of the reference population. A negative Z-score means the measured bone mineral density values are lower (worse) the reference mean, while positive Z-scores mean they are above/higher. Bone mineral density Z-scores ≤ -2 indicates low bone density.

Outcome measures

Outcome measures
Measure
Group A
n=34 Participants
Female participants
Group B
n=19 Participants
Male Participants
Femoral Neck Bone Mineral Density Z-scores
-0.95 Z-score
Interval -2.7 to 2.4
-0.60 Z-score
Interval -2.3 to 4.0

PRIMARY outcome

Timeframe: Baseline

Patient-reported outcome measure of pain impact in the preceding 7 days before bone density measurements. The Adult Sickle Cell Quality of Life Measurement System (ASCQ-Me) pain impact T-scores range from about 30-100. The ASCQ-Me pain impact T-score has standardized mean T-score of 50 and standard deviation of 10, which were derived from a reference population of ambulatory adult with sickle cell disease across the United States. ASCQ-Me pain impact T-scores less than 50 are lower/worse than the reference mean (more severe pain impact), while pain impact T-scores greater than 50 are above/better than the reference mean (less severe pain impact)

Outcome measures

Outcome measures
Measure
Group A
n=23 Participants
Female participants
Group B
n=30 Participants
Male Participants
Adult Sickle Cell Quality of Life Measurement System (ASCQ-Me) Pain Impact T-scores
47.1 T-score
Interval 42.4 to 52.8
52.4 T-score
Interval 45.3 to 56.5

SECONDARY outcome

Timeframe: Baseline

Population: Statistical analysis of spinal deformity index is ongoing. Complete results will be provided by February 2026.

The spinal deformity index (SDI) is a semi-quantitative measure of number and severity of vertebral fractures observed on lateral spine X-rays of the thoracolumbar spine. To calculate the SDI, vertebrae are assigned a score as follows: 0 (no fracture), 1 (mild fracture), 2 (moderate fracture), and 3 (severe fracture). The total SDI is the summation of all T12-L4 vertebrae measured on the lateral spine X-rays. Minimum SDI =0 and Maximum SDI=15. Higher scores mean increased (worse) fracture burden, lower scores mean decreased (less) fracture burden.

Outcome measures

Outcome measures
Measure
Group A
n=23 Participants
Female participants
Group B
n=30 Participants
Male Participants
Spinal Deformity Index
2.00 score on a scale
Standard Deviation 2.71
3.13 score on a scale
Standard Deviation 3.98

Adverse Events

SCD Bone Pain Study Cohort

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Oyebimpe Adesina, MD, MS

University of California Davis Comprehensive Cancer Center

Phone: 9167035166

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place